ATE45955T1 - In stellung 10 substituierte steroide, ihre herstellung, zwischenprodukte in ihrer herstellung, ihre anwendung als arzneimittel und pharmazeutische zusammensetzungen,die sie enthalten. - Google Patents

In stellung 10 substituierte steroide, ihre herstellung, zwischenprodukte in ihrer herstellung, ihre anwendung als arzneimittel und pharmazeutische zusammensetzungen,die sie enthalten.

Info

Publication number: ATE45955T1
Authority: AT; Austria
Prior art keywords: manufacture; optionally substituted; group; products; image
Prior art date: 1985-01-14

Application number

AT86400057T

Other languages

English (en)

Inventor

Jean-Georges Teutsch

Germain Costerousse

Vesperto Torelli

Daniel Philibert

Original Assignee

Roussel Uclaf

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-01-14

Filing date

1986-01-13

Publication date

1989-09-15

1986-01-13 Application filed by Roussel Uclaf filed Critical Roussel Uclaf

1989-09-15 Application granted granted Critical

1989-09-15 Publication of ATE45955T1 publication Critical patent/ATE45955T1/de

Links

150000003431 steroids Chemical class 0.000 title abstract 2
238000004519 manufacturing process Methods 0.000 title 2
239000013067 intermediate product Substances 0.000 title 1
229940126601 medicinal product Drugs 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
125000004432 carbon atom Chemical group C* 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
125000002252 acyl group Chemical group 0.000 abstract 1
125000000304 alkynyl group Chemical group 0.000 abstract 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 abstract 1
239000011203 carbon fibre reinforced carbon Substances 0.000 abstract 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 abstract 1
239000003862 glucocorticoid Substances 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
125000005017 substituted alkenyl group Chemical group 0.000 abstract 1
125000000547 substituted alkyl group Chemical group 0.000 abstract 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 1
229920002554 vinyl polymer Polymers 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0081—Substituted in position 17 alfa and 17 beta
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0081—Substituted in position 17 alfa and 17 beta
- C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
- C07J1/0096—Alkynyl derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/006—Ketals at position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
- C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Immunology (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Toxicology (AREA)
Cardiology (AREA)
Child & Adolescent Psychology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Anesthesiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT86400057T 1985-01-14 1986-01-13 In stellung 10 substituierte steroide, ihre herstellung, zwischenprodukte in ihrer herstellung, ihre anwendung als arzneimittel und pharmazeutische zusammensetzungen,die sie enthalten. ATE45955T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR8500434A FR2576025B1 (fr)	1985-01-14	1985-01-14	Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
EP86400057A EP0188396B1 (de)	1985-01-14	1986-01-13	In Stellung 10 substituierte Steroide, ihre Herstellung, Zwischenprodukte in ihrer Herstellung, ihre Anwendung als Arzneimittel und pharmazeutische Zusammensetzungen,die sie enthalten

Publications (1)

Publication Number	Publication Date
ATE45955T1 true ATE45955T1 (de)	1989-09-15

Family

ID=9315230

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT86400057T ATE45955T1 (de)	1985-01-14	1986-01-13	In stellung 10 substituierte steroide, ihre herstellung, zwischenprodukte in ihrer herstellung, ihre anwendung als arzneimittel und pharmazeutische zusammensetzungen,die sie enthalten.

Country Status (14)

Country	Link
US (1)	US4753932A (de)
EP (1)	EP0188396B1 (de)
JP (2)	JPH0772193B2 (de)
KR (1)	KR930005993B1 (de)
AT (1)	ATE45955T1 (de)
AU (1)	AU582618B2 (de)
CA (1)	CA1266466A (de)
DE (1)	DE3665306D1 (de)
DK (1)	DK169077B1 (de)
ES (1)	ES8801509A1 (de)
FR (1)	FR2576025B1 (de)
HU (1)	HU196825B (de)
IE (1)	IE59010B1 (de)
ZA (1)	ZA86146B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2639045B2 (fr) *	1982-03-01	1994-07-29	Roussel Uclaf	Nouveaux produits derives de la structure 3-ceto-delta-4,9-19-nor steroides et leur application comme medicaments
FR2576025B1 (fr) *	1985-01-14	1987-01-23	Roussel Uclaf	Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
US5446178A (en) *	1987-03-18	1995-08-29	Schering Aktiengesellschaft	Process for preparing 19,11β-bridged steroids
DE3708942A1 (de) *	1987-03-18	1988-09-29	Schering Ag	19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
US4910191A (en) *	1988-06-28	1990-03-20	Merrell Dow Pharmaceuticals Inc.	19-substituted progesterone derivatives useful as 19-hydroxylase inhibitors
DE3822770A1 (de) *	1988-07-01	1990-01-04	Schering Ag	13-alkyl-11ss-phenylgonane
DE3917274A1 (de) *	1989-05-24	1990-11-29	Schering Ag	9(alpha)-hydroxy-19, 11(beta)-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2647452A1 (fr) *	1989-05-24	1990-11-30	Theramex	Nouveaux 19-nor steroides 6-methyles leurs procedes d'obtention, les compositions pharmaceutiques en renfermant et leur conversion en 19-nor pregnadienes 17-substitues
CN1055929C (zh) *	1993-09-20	2000-08-30	中国科学院上海有机化学研究所	三氟甲基甾体化合物及其制备方法
JP3862295B2 (ja) *	1993-09-30	2006-12-27	独立行政法人理化学研究所	抗肥満剤
US5780220A (en) *	1994-05-19	1998-07-14	Trustees Of The University Of Pennsylvania	Methods and compositions for inhibiting HIV replication
US5639598A (en) *	1994-05-19	1997-06-17	The Trustees Of The University Of Pennsylvania	Method and kit for identification of antiviral agents capable of abrogating HIV Vpr-Rip-1 binding interactions
CN1055930C (zh) *	1994-10-08	2000-08-30	中国科学院上海有机化学研究所	一种甾体烯醇多氟烃基磺酸酯化合物及其衍生物、用途和制备方法
CN1061983C (zh) *	1996-11-29	2001-02-14	中国科学院上海有机化学研究所	一种4-三氟甲基-3-酮甾体化合物及其合成方法
CN1061987C (zh) *	1997-08-28	2001-02-14	中国科学院上海有机化学研究所	6,10－亚甲基－19－降－甾体－4－烯－3－酮化合物及其合成
US6090798A (en) *	1997-12-19	2000-07-18	Alcon Laboratories, Inc.	Treatment of GLC1A glaucoma with glucocorticoid antagonists
CN1064369C (zh) *	1998-05-15	2001-04-11	中国科学院上海有机化学研究所	甾醇多氟芳酸酯、合成方法及其用途
ATE473759T1 (de)	1998-05-22	2010-07-15	Univ Leland Stanford Junior	Bifunktionelle moleküle sowie darauf basierende therapien.
DE69920717T2 (de) *	1998-07-30	2005-10-06	Abbott Laboratories, Abbott Park	Glucocorticoid selektive wirkstoffe
HK1042889B (zh) *	1999-04-30	2006-12-29	辉瑞产品公司	糖皮质激素受体调制剂
US7713989B2 (en)	2000-04-27	2010-05-11	Dow Robert L	Glucocorticoid receptor modulators
ES2246292T3 (es)	2000-10-30	2006-02-16	Pfizer Products Inc.	Moduladores de receptor glucocorticoide.
EP1581234A4 (de) *	2002-11-05	2007-09-12	Corcept Therapeutics Inc	Verfahren zur behandlung von migräne
US8080682B2 (en)	2006-08-24	2011-12-20	University Of Tennessee Research Foundation	Substituted acylanilides and methods of use thereof
WO2004112720A2 (en) *	2003-06-20	2004-12-29	Viral Genomix, Inc.	Antiviral compositions and methods of using the same
CN1221563C (zh) *	2003-07-16	2005-10-05	中国科学院上海有机化学研究所	16－脱氢孕烯醇酮及其同类物的生产方法
CN102379684B (zh)	2005-04-28	2014-11-19	普罗透斯数字保健公司	药物信息系统
US9062126B2 (en)	2005-09-16	2015-06-23	Raptor Pharmaceuticals Inc.	Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
WO2008093227A1 (en)	2007-02-02	2008-08-07	Pfizer Products Inc.	Tricyclic compounds and their use as glucocorticoid receptor modulators
EP2398500B1 (de)	2009-02-20	2019-03-13	2-BBB Medicines B.V.	Arzneiabgabesystem auf glutathion-basis
ES2942923T3 (es)	2009-05-06	2023-06-07	Laboratory Skin Care Inc	Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas
PL2576582T3 (pl)	2010-05-26	2020-06-29	Corcept Therapeutics, Inc.	Leczenie dystrofii mięśniowej
US10258596B2 (en)	2012-07-13	2019-04-16	Gtx, Inc.	Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9622992B2 (en)	2012-07-13	2017-04-18	Gtx, Inc.	Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10987334B2 (en)	2012-07-13	2021-04-27	University Of Tennessee Research Foundation	Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9969683B2 (en)	2012-07-13	2018-05-15	Gtx, Inc.	Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10314807B2 (en)	2012-07-13	2019-06-11	Gtx, Inc.	Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en)	2012-07-13	2017-08-29	Gtx, Inc.	Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
HUE052574T2 (hu)	2012-07-13	2021-05-28	Oncternal Therapeutics Inc	Eljárás mellrákok kezelésére szelektív ösztrogén receptor modulátorral (SARM)
WO2016140867A1 (en)	2015-03-02	2016-09-09	Corcept Therapeutics, Inc.	Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors
US10610534B2 (en)	2015-03-30	2020-04-07	Corcept Therapeutics, Inc.	Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
KR20180052120A (ko)	2015-08-13	2018-05-17	코어셉트 쎄라퓨틱스, 잉크.	Acth-의존성 쿠싱 증후군을 감별 진단하는 방법
KR102197526B1 (ko)	2016-01-19	2020-12-31	코어셉트 쎄라퓨틱스 인코포레이티드	이소성 쿠싱 증후군의 감별 진단
CN107200770B (zh) *	2016-03-18	2019-11-01	华东师范大学	特拉司酮合成中环氧异构体的高效分离和循环利用方法
SG11201908790PA (en)	2017-03-31	2019-10-30	Corcept Therapeutics Inc	Glucocorticoid receptor modulators to treat cervical cancer
MX393313B (es)	2017-06-20	2025-03-24	Corcept Therapeutics Inc	Metodos de tratamiento de tumores neuroepiteliales usando moduladores selectivos del receptor de glucocorticoide.
AU2020239920A1 (en)	2019-03-18	2021-11-04	Arnold L. Newman	Method of improving insulin sensitivity
JP2024500748A (ja)	2020-12-18	2024-01-10	インスティルバイオ（ユーケイ）リミテッド	腫瘍浸潤リンパ球の処理

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR1380411A (fr) *	1962-02-24	1964-12-04	Roussel Uclaf	Nouveau procédé de préparation de 10 beta-allyl-stéroïdes et produits utilisésdans ce procédé
US3132138A (en) *	1962-02-24	1964-05-05	Roussel Uclaf	Preparation of 10beta-allyl steroids and intermediates
FR2522328B1 (fr) *	1982-03-01	1986-02-14	Roussel Uclaf	Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
FR2569408B1 (fr) *	1984-08-24	1986-10-03	Roussel Uclaf	Nouveaux steroides substitues en position 10 par un radical comportant une double ou triple liaison, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant
FR2576025B1 (fr) *	1985-01-14	1987-01-23	Roussel Uclaf	Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant

1985
- 1985-01-14 FR FR8500434A patent/FR2576025B1/fr not_active Expired
1986
- 1986-01-08 ZA ZA86146A patent/ZA86146B/xx unknown
- 1986-01-13 DK DK013286A patent/DK169077B1/da not_active IP Right Cessation
- 1986-01-13 AT AT86400057T patent/ATE45955T1/de not_active IP Right Cessation
- 1986-01-13 EP EP86400057A patent/EP0188396B1/de not_active Expired
- 1986-01-13 CA CA000499414A patent/CA1266466A/fr not_active Expired - Fee Related
- 1986-01-13 ES ES550822A patent/ES8801509A1/es not_active Expired
- 1986-01-13 HU HU86163A patent/HU196825B/hu not_active IP Right Cessation
- 1986-01-13 DE DE8686400057T patent/DE3665306D1/de not_active Expired
- 1986-01-13 IE IE8386A patent/IE59010B1/en not_active IP Right Cessation
- 1986-01-14 US US06/818,884 patent/US4753932A/en not_active Expired - Lifetime
- 1986-01-14 AU AU52283/86A patent/AU582618B2/en not_active Ceased
- 1986-01-14 JP JP61004436A patent/JPH0772193B2/ja not_active Expired - Fee Related
- 1986-01-14 KR KR1019860000163A patent/KR930005993B1/ko not_active Expired - Fee Related
1994
- 1994-12-27 JP JP6336865A patent/JP2687209B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP0188396B1 (de)	1989-08-30
US4753932A (en)	1988-06-28
JPS61168029A (ja)	1986-07-29
DE3665306D1 (en)	1989-10-05
JPH0772193B2 (ja)	1995-08-02
IE860083L (en)	1986-07-14
FR2576025B1 (fr)	1987-01-23
EP0188396A3 (en)	1986-12-10
JPH07316185A (ja)	1995-12-05
CA1266466A (fr)	1990-03-06
AU5228386A (en)	1986-07-17
AU582618B2 (en)	1989-04-06
HU196825B (en)	1989-01-30
FR2576025A1 (fr)	1986-07-18
DK13286A (da)	1986-07-15
ES550822A0 (es)	1988-01-16
DK13286D0 (da)	1986-01-13
KR930005993B1 (ko)	1993-07-01
IE59010B1 (en)	1993-12-03
ES8801509A1 (es)	1988-01-16
JP2687209B2 (ja)	1997-12-08
HUT41047A (en)	1987-03-30
ZA86146B (en)	1987-03-25
DK169077B1 (da)	1994-08-08
EP0188396A2 (de)	1986-07-23
KR860005832A (ko)	1986-08-13

Legal Events

Date	Code	Title	Description
1990-01-15	UEP	Publication of translation of european patent specification
2004-10-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE3665306D1 (en)	1989-10-05	Steroids substituted in position 10, their preparation and intermediates obtained in their preparation, their use as medicaments and pharmaceutical compositions containing them
PT79735A (de)	1985-01-01	11beta-aryl-estradiene deren herstellung und diese enthaltende pharmazeutische praeparate
ATE1814T1 (de)	1982-12-15	9-hydroxyalkylpurine, verfahren zu ihrer herstellung und 9-hydroxyalkylpurine als aktive mittel enthaltende therapeutische zusammensetzung.
NZ332608A (en)	2000-01-28	alkyl 17-alpha-dichloroacetoxy-11- beta-hydroxy-androsta-1,4-diene-3-one-17-beta-carboxylates and medicaments
DE59005254D1 (de)	1994-05-11	24-Homo-Vitamin-D-Derivate, Verfahren zu ihrer Herstellung; diese Derivate enthaltende pharmazeutische Präparate sowie deren Verwendung als Arzneimittel.
FR2610933B1 (fr)	1989-06-09	Nouveaux 19-nor steroides substitues en position 7, leur preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant
SE7907224L (sv)	1979-08-30	Delta 15 -steroider till anvendning i antikonceptionspreparat
ATE35995T1 (de)	1988-08-15	6,6-ethylen-15,16-methylen-3-oxo-17alpha-pregn- en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praparate.
ATE28752T1 (de)	1987-08-15	1-alkyl-androsta-1,4-dien-3,17-dione, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate.
ES2111616T3 (es)	1998-03-16	Compuestos de ciclohexapeptidil bisamina.
ATE150466T1 (de)	1997-04-15	Neue 19-nor-steroide mit einer 11-beta- phenoxysulfonamid- oder 11-beta- phenoxysulfonylurea-gruppe, verfahren und zwischenprodukte zu ihrer herstellung sowie medikamenten und pharmazeutische präparate davon
ZA793453B (en)	1980-06-25	New 3,20-dioxo-4,9-diene-21-hydroxyl steroid derivatives,a process for preparing them,their use as medicaments and the pharmaceutical compositions containing them
IE42168L (en)	1976-04-18	1-alpha-hydroxy and alkanoyloxy-steroids
ATE16108T1 (de)	1985-11-15	Steroide die, in stellung 17 verestert sind, und in stellung 21 eine thioestergruppe enthalten, verfahren zu ihrer herstellung und ihre anwendung als arzneimittel.
EP0137434A3 (en)	1986-01-08	Estrane and androstane derivatives, process for their preparation and pharmaceutical preparations containing them
ATE430T1 (de)	1981-12-15	16-alpha-alkylsteroide, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
ATE22085T1 (de)	1986-09-15	17-alpha-alkyl-17-beta-hydroxy-1-alpha-methyl-4 androsten-3-one, verfahren zu ihrer herstellung und pharmazeutische praeparate, die diese verbindungen enthalten.
ATE175418T1 (de)	1999-01-15	15,15-dialkylsubstituierte östradiolderivate
ES489143A1 (es)	1980-08-16	Procedimiento de preparacion de nuevos derivados esteroides alcohilados en la posicion 7
FR2422689A1 (fr)	1979-11-09	Steroides de la serie du pregnane a groupe hydroxy etherifie en position 17 et medicaments qui en contiennent
IE43985L (en)	1977-05-11	D-homosteroids
ATE18408T1 (de)	1986-03-15	11beta-chlor-delta15-steroide, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.